Sonnet BioTherapeutics to present at Cytokine-Based Drug Development Summit

Sonnet BioTherapeutics announced that John Cini, PhD, Chief Scientific Officer and Co-Founder, and Richard Kenney, MD, Chief Medical Officer, will be featured speakers at the 4th Annual Cytokine-Based Drug Development Summit in Boston, Massachusetts, June 27-29. In the SB211 study, patients are being randomized to one of three treatment groups that receive 20 microgram SON-080, 60 microgram SON-080, or a matching placebo in a blinded fashion, three times a week for 12 weeks. As of June 22, 2023, seven patients have been enrolled. While the groups remain blinded, doses have been tolerated well with some mild-to-moderate transient injection site reactions. The company said, “As the protocol requires a total of nine patients to be dosed for at least two weeks before a safety review by the Data Safety Monitoring Board, we expect the DSMB to meet during the third quarter of 2023. Following the completion of the DSMB review, we anticipate announcing the initial safety data.”